Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: a feasibility study - PubMed (original) (raw)
. 2002 Jan-Feb;22(1A):69-74.
Affiliations
- PMID: 12017336
Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: a feasibility study
Helen M Coley et al. Anticancer Res. 2002 Jan-Feb.
Abstract
This in vitro feasibility study has assessed a number of techniques and their applicability when looking at the role of multidrug resistance (MDR) in solid tumours. Fresh tumour material was obtained from 34 patients, (11 previously treated, 23 untreated) with ovarian adenocarcinoma. Doxorubicin sensitivity was measured using the MTT assay +/- the cyclosporins, Pgp expression was assessed by immunocytochemistry with the MRK-16 MoAb and flow cytometry was used to assess intracellular drug accumulation +/- PSC 833. 85% of samples showed some evidence of modest chemosensitisation by the cyclosporins (median 1.74-fold). We saw a marked variation in the number of Pgp positive cells between patients (1-87%, median 31%). 63% of samples tested showed an enhancement of DNR accumulation in the presence of PSC 833, with a median increase of 7% (sample range 0-29%). The present study highlights some of the technical difficulties encountered when working with fresh tumour material ex vivo. We conclude that screening of patients for their suitability to enter clinical trials incorporating MDR modulating agents is technically demanding, but feasible.
Similar articles
- Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma.
Coley HM, Verrill MW, Gregson SE, Odell DE, Fisher C, Judson IR. Coley HM, et al. Eur J Cancer. 2000 May;36(7):881-8. doi: 10.1016/s0959-8049(00)00032-0. Eur J Cancer. 2000. PMID: 10785593 - Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562.
Sargent JM, Williamson CJ, Yardley C, Taylor CG, Hellmann K. Sargent JM, et al. Br J Cancer. 2001 Apr 6;84(7):959-64. doi: 10.1054/bjoc.2001.1697. Br J Cancer. 2001. PMID: 11286477 Free PMC article. - Reversal of multidrug resistance: lessons from clinical oncology.
Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T. Bates SF, et al. Novartis Found Symp. 2002;243:83-96; discussion 96-102, 180-5. Novartis Found Symp. 2002. PMID: 11990784 Review. - Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin.
Michieli M, Damiani D, Michelutti A, Melli C, Ermacora A, Geromin A, Fanin R, Russo D, Baccarani M. Michieli M, et al. Haematologica. 1996 Jul-Aug;81(4):295-301. Haematologica. 1996. PMID: 8870372 - Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB. Kaye SB. Curr Opin Oncol. 1998 Aug;10 Suppl 1:S15-9. Curr Opin Oncol. 1998. PMID: 9801854 Review.
Cited by
- The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models.
Martin C, Walker J, Rothnie A, Callaghan R. Martin C, et al. Br J Cancer. 2003 Oct 20;89(8):1581-9. doi: 10.1038/sj.bjc.6601300. Br J Cancer. 2003. PMID: 14562035 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous